Bcl-2 family regulation of neuronal development and neurodegeneration  by Akhtar, Rizwan S. et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1644 (2004) 189–203Review
Bcl-2 family regulation of neuronal development and neurodegeneration
Rizwan S. Akhtara,b, Jayne M. Nessc, Kevin A. Rotha,*
aDivision of Neuropathology, Department of Pathology, University of Alabama at Birmingham, 1530 Third Avenue South, SC 961,
Birmingham, AL 35294-0017, USA
bDepartment of Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
cDivision of Pediatric Neurology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294, USAReceived 14 April 2003; accepted 27 October 2003Abstract
Neuronal cell death is a key feature of both normal nervous system development and neuropathological conditions. The Bcl-2 family, via
its regulation of both caspase-dependent and caspase-independent cell death pathways, is uniquely positioned to critically control neuronal
cell survival. Targeted gene disruptions of specific bcl-2 family members and the generation of transgenic mice overexpressing anti- or pro-
apoptotic Bcl-2 family members have confirmed the importance of the Bcl-2 family in the nervous system. Data from studies of human brain
tissue and experimental animal models of neuropathological conditions support the hypothesis that the Bcl-2 family regulates cell death in the
mature nervous system and suggest that pharmacological manipulation of Bcl-2 family action could prove beneficial in the treatment of
human neurological conditions such as stroke and neurodegenerative diseases.
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Regulated cell death plays an important role in the
development and survival of multi-cellular organisms. Dur-
ing embryogenesis, programmed cell death results in the
regression of phylogenetically vestigial structures, the
sculpting of organs, and establishment of appropriate cell
numbers [1,2]. In the mature animal, apoptotic and non-
apoptotic forms of regulated cell death are involved in both
normal cellular turnover and in the biological response to
pathological insults. The significance of cell death regula-
tion is clearly evidenced in the mammalian nervous system
where altered levels of programmed cell death may lead to a
wide spectrum of neurodevelopmental anomalies. Similarly,
increased cell death in the mature nervous system may lead
to a variety of neurodegenerative pathologies. For these
reasons, the Bcl-2 family has been the focus of intense
neuroscientific interest.
The Bcl-2 family consists of three major subgroups [3].
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termed Bcl-2 homology (BH) domains. When overex-
pressed, these proteins inhibit cell death responsiveness.
Multi-domain pro-death Bcl-2 family members, the second
subgroup, typically possess at least BH1 and BH2 domains
and include Bax, Bak, Bok, and Bcl-XS. The third, and most
structurally diverse subgroup, is the BH3 domain-only pro-
death subgroup. BH3-only molecules include Bim, Bid,
Bcl-2-associated death protein (Bad), death protein 5/har-
akiri (DP5/Hrk), Puma, and Noxa and induce cell death
following a variety of stimuli. Bcl-2 family members can
heterodimerize via their BH domains and execution of a cell
death stimulus may depend on the intracellular balance
between various Bcl-2 subfamily members [4]. The subcel-
lular distribution of Bcl-2 family members varies from
purely cytosolic to predominantly mitochondrial, to being
present in multiple intracellular membranous compartments
[5]. Bcl-2 family regulation of mitochondrial cytochrome c
release and mitochondrial function plays a large part in
controlling cell death [3,6]. The death-promoting effects of
Bcl-2 family action may occur secondary to downstream
caspase activation, resulting in an apoptotic cellular pheno-
type, or be caspase-independent and display alternative
degenerative morphological features. Determination of the
significance of the Bcl-2 family in the regulation of neuronal
R.S. Akhtar et al. / Biochimica et Biophysica Acta 1644 (2004) 189–203190cell death and that of individual family members in partic-
ular has been greatly aided by the generation of transgenic
mice. The overexpression of Bcl-2 and/or Bcl-XL in neurons
has clearly demonstrated a significant neuroprotective func-
tion for these molecules in the mature nervous system.
Targeted gene disruptions have similarly proved valuable
in demonstrating critical roles for specific Bcl-2 family
members in regulating neuronal programmed cell death.
Genetically modified mice have also been useful in demon-
strating a potential role for Bcl-2 family regulation of
neuronal cell death in a variety of neuropathological con-
ditions. Combined with direct studies of human tissues,
these investigations strongly implicate the Bcl-2 family as a
key regulator of neuronal cell fate.2. Bcl-2 family regulation of neuronal programmed cell
death
2.1. Bcl-2
Bcl-2 is the prototypical member of the Bcl-2 family [3].
Bcl-2 mRNA and protein are present at relatively high
levels in the developing nervous system and decline signif-
icantly in the postnatal brain [7,8]. Bcl-2 expression is
maintained at relatively high levels in sensory and sympa-
thetic neurons in the adult peripheral nervous system [8,9].
The role of Bcl-2 in neuronal programmed cell death has
been examined using several experimental approaches.
Trophic factor withdrawal-induced death of a variety of
neuronal cell lines and primary neuron populations, an in
vitro model of target-dependent programmed cell death, is
inhibited by Bcl-2 overexpression [10–13]. Similarly, neu-
ronal overexpression of Bcl-2 in transgenic mice increases
the number of neurons in many brain regions by inhibiting
naturally occurring neuronal cell death [11,14]. These over-
expression studies, however, only indicate a potential role
for endogenous Bcl-2 in regulating programmed cell death
since other anti-apoptotic family members may play a more
significant role in vivo. Targeted disruption of the bcl-2Fig. 1. Bcl-XL deficiency causes extensive death of neurons in the developing nerv
cord show occasional neurons with apoptotic histological features undergoing prog
an arrow) and massive numbers of apoptotic neurons in the Bcl-XL-deficient spinagene has indeed revealed selective effects of endogenous
Bcl-2 expression on different neuronal populations.
Despite high levels of Bcl-2 mRNA and protein expres-
sion in both neural precursor cells and in postmitotic
neurons in the embryonic brain, Bcl-2-deficient embryos
show relatively normal nervous development and no signif-
icant increase in neuronal programmed cell death. Bcl-2-
deficient mice do, however, exhibit a profound loss of
motoneurons, sympathetic neurons, and sensory neurons
during early postnatal life [15–17]. Unlike neurons in the
brain, these peripheral neuronal populations normally ex-
hibit significant baseline Bcl-2 expression during the neo-
natal period [8]. The death of these neurons in Bcl-2-
deficient mice occurs after the normal peak of programmed
cell death in these populations, suggesting that Bcl-2 may
play a more important role in maintenance of their survival
rather than in regulating their programmed cell death per se.
2.2. Bcl-XL
The bcl-x gene can be alternatively spliced to produce
two major protein isoforms, Bcl-XL and Bcl-XS [18,19].
Bcl-XL is highly homologous to Bcl-2 and is expressed at
relatively high levels in both the embryonic and mature
nervous systems. In contrast, Bcl-XS is pro-apoptotic and is
found only at low levels in the mammalian nervous system
[19]. Bcl-XL expression is up-regulated in immature neu-
rons as they migrate away from the mitotically active
ventricular zone and remains highly expressed in mature
neurons in the adult brain [20,21]. Targeted gene disruption
of bcl-x has revealed a significant role for Bcl-XL in
regulating neuronal programmed cell death [20]. Bcl-XL-
deficiency is lethal around embryonic day (E) 13.5 second-
ary to extensive hematopoietic cell apoptosis; analysis of
Bcl-XL-deficient embryos prior to this point reveals massive
cell death of immature neurons throughout the developing
nervous system (Fig. 1) [20]. Bcl-XL expression is low in
neural precursor cells and Bcl-XL deficiency has no obvious
effect on this cell population [20]. The increased suscepti-
bility of Bcl-XL-deficient neurons to death stimuli is reca-ous system. Hematoxylin and eosin stained sections of the E12 mouse spinal
rammed cell death in the wild-type embryo (left panel; example indicated by
l cord (right panel; examples indicated by arrows). Scale bars equal 20 Am.
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x / embryos were markedly sensitive to trophic factor
deprivation and other cell death stimuli such as genotoxic
injury and chloroquine administration [22–24]. Together,
these results suggest that the survival of newly post-mitotic
immature neurons depends on Bcl-XL function.
The increased programmed cell death observed in the
Bcl-XL-deficient nervous system appears to involve activa-
tion of the intrinsic, mitochondrial-dependent, apoptotic
death pathway. Bcl-XL-deficient embryos exhibit a marked
increase in activated caspase-3-like activity in the develop-
ing nervous system [21]. The increased neuronal cell death
observed in these embryos is completely blocked by con-
comitant deficiency in caspase-9 or caspase-3 [21,25]. Thus,
for immature neurons in the developing brain, caspase-
dependent apoptotic cell death is inhibited by endogenous
expression of Bcl-XL. In addition to Bcl-XL and Bcl-2,
recent studies also suggest a role for Bcl-w in neuronal cell
death [26–29]. However, Bcl-w deficiency does not cause
obvious neurodevelopmental abnormalities [30]. Further
studies will need to address the functional redundancy of
anti-apoptotic Bcl-2 family members.
2.3. Bax
The pro-apoptotic molecule Bax was originally identified
as a binding partner for Bcl-2 [4]. Bax is expressed in both
the embryonic and adult brain and can heterodimerize with
Bcl-2, Bcl-XL, Mcl-1, and A1 [4,31–33]. Current data
suggest that Bax regulates cytochrome c release from
mitochondria, perhaps via formation of the mitochondrial
transition pore [6,34]. Anti-apoptotic members of the Bcl-2
family may heterodimerize or hetero-oligomerize with Bax
to inhibit Bax function. Targeted gene disruption of bax has
demonstrated an important role for Bax in triggering neu-
ronal programmed cell death.
In the developing nervous system, programmed cell
death of synapse-bearing neurons during a period of com-
petition for target-derived neurotrophic support helps deter-
mine neuronal cell numbers. Bax-deficient mice exhibit
markedly decreased neuronal programmed cell death in a
variety of sites including brainstem, cerebellum, dorsal root
ganglia, hippocampus, and spinal cord, with resultant in-
creased neuron numbers in these areas [35,36]. This phe-
nomenon is recapitulated in vitro in neonatal sympathetic
neuron cultures. Following nerve growth factor (NGF)
withdrawal, wild-type sympathetic neurons exhibit redistri-
bution of cytochrome c from the mitochondria to the cytosol
and undergo fairly rapid apoptotic death [35,37]. In contrast,
Bax-deficient sympathetic neurons do not show increased
cytosolic cytochrome c and survive for weeks after NGF
withdrawal [37]. Bax-deficient neurons under these condi-
tions exhibit reduced soma size and axon diameter. Neuro-
nal atrophy is also observed in vivo in some populations of
Bax-deficient neurons, indicating that neurons ‘‘rescued’’
from programmed cell death may not be completely normal[35,36]. Interestingly, in certain models of trophic factor
withdrawal-induced neuronal death, Bax may not play a
critical role. For example, in NGF-deprived trigeminal
neurons, Bax-deficiency delays, but does not prevent, cell
death [38]. Also, in cultured chick sensory and ciliary
neurons, Bax overexpression may have a pro-survival action
following trophic factor withdrawal [39]. Bax may also play
a role in regulating activity dependent neuronal apoptosis.
Cerebellar granule neurons (CGNs) undergo apoptosis when
cultured in non-depolarizing, serum-free media, and Bax-
deficient CGNs are protected from this apoptotic stimulus
[40,41].
Targeted disruptions of both bax and bcl-x revealed
important roles for these Bcl-2 family members in neuronal
programmed cell death. To examine the potential interaction
of Bax and Bcl-XL in neuronal cell death regulation,
bax  / /bcl-x  / embryos were generated. Bax, Bcl-XL
dual-deficient embryos showed complete protection from
Bcl-XL deficiency-induced neuronal apoptosis [42]. The
neuroprotective effect of Bax deficiency on Bcl-XL-deficient
cells was also observed in vitro in primary telencephalic
neuronal cell cultures [42]. Bax deficiency did not, however,
rescue Bcl-XL-deficient mice from embryonic lethality, in-
dicating that Bcl-XL has both Bax-dependent and Bax-
independent actions on different cell types [42].
Although Bax deficiency inhibits programmed cell death
in many neuronal populations, Bax-independent death path-
ways also contribute significantly to nervous system mor-
phogenesis. Like Bax-deficient mice, mice with targeted
gene disruptions of caspase-9, apaf-1, and caspase-3 exhibit
markedly reduced programmed cell death. However, unlike
Bax-deficient mice, a significant number of embryos with
caspase-9, apaf-1, and caspase-3 gene disruptions also
possess gross structural brain abnormalities, including neu-
ral precursor cell hyperplasia and forebrain exencephaly
[43–46]. These observations suggest that programmed cell
death in neural precursor cells may be caspase-dependent
but Bax-independent. This conclusion requires caution,
however, for several reasons. First, the neurodevelopmental
effects of caspase-9, apaf-1, and caspase-3 gene disruption
are incompletely penetrant and strain-dependent. For exam-
ple, caspase-3 deficiency causes perinatal lethality and
severe neurodevelopmental pathology in 129x1/SvJ mice.
In contrast, the same gene disruption in C57BL/6J mice
leads to minimal neuropathological abnormalities [47]. This
result indicates that direct comparisons between gene dis-
ruptions on different or mixed genetic backgrounds are
problematic. Second, Bcl-2 family members have overlap-
ping actions, thereby raising the possibility that changes in
the expression of other family members may compensate for
Bax deficiency.
2.4. Bak
The pro-apoptotic molecule Bak was simultaneously
identified in a yeast two-hybrid screen with an adenoviral
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widely expressed in most murine tissues, and recently a
neuron-specific Bak splice product has been described [51].
Bak is structurally similar to Bax and, like Bax, may
regulate mitochondrial cytochrome c release and apoptotic
death in a variety of cell types [48,52]. Bak-deficient mice,
like Bax-deficient mice, show no gross developmental
pathology; however, overexpression of Bak can accelerate
trophic factor withdrawal-induced death in sympathetic
neurons [48,50]. Bak deficiency has no effect on cyto-
chrome c release and cell death in sympathetic neurons
following trophic factor withdrawal, whereas Bax deficien-
cy prevents these changes [53].
Given the potential functional overlap between Bax and
Bak, bax  / /bak  / mice were generated [54]. Bax,
Bak dual-deficient mice show extensive perinatal lethality,
persistent interdigital webs, imperforate vagina, and other
developmental abnormalities, indicating that Bax and Bak
may act in concert to affect cell death [54]. The potent pro-
survival effect of combined Bax and Bak deficiency is
well demonstrated in neural precursor cells. DNA damage
to neural precursor cells, either in vivo or in vitro, induces
p53-, Apaf-1-, and caspase-9-dependent apoptosis [55].
Alone, neither Bax nor Bak deficiency has any effect on
DNA damage-induced neural precursor cell death [55,56].
However, neural precursor cells lacking both Bax and Bak
are completely protected from g-irradiation and chemo-
therapeutic-induced death, both in vivo and in vitro [56].
Bax, Bak dual-deficient neonatal and young adult mice
exhibit increased numbers of periventricular neural precur-
sor cells, indicating that Bax and Bak can combine to
affect neural precursor cell survival in vivo (Fig. 2).
Interestingly, dual Bax, Bak deficiency produces a less
severe neurodevelopmental phenotype than that seen in
affected caspase-9-, Apaf-1-, and caspase-3-deficient em-
bryos. In total, these findings suggest that neural precursor
cell death is regulated by developmental stage- and/or
stimulus-specific molecular pathways which differentially
involve Bax and Bak.Fig. 2. Bax, Bak dual deficiency affects postnatal neural precursor cell survival. H
neural precursor cells in the periventricular region of the wild-type forebrain (left
population in the forebrain of a mouse lacking both Bax and Bak (right panel). S2.5. Bid
Bid is a member of the BH3-only pro-apoptotic subgroup
of the Bcl-2 family, and was isolated as an interacting
partner of Bcl-2 and Bax [57]. Bid regulates cell death by
interacting with both pro- and anti-apoptotic multi-domain
Bcl-2 family members such as Bcl-2, Bcl-XL, Bax and Bak
[57–61]. This interaction requires an intact BH3 domain in
Bid and triggers caspase-dependent apoptosis [57,59,60].
Bid plays an important role in linking extrinsic, death
receptor signaling with intrinsic, mitochondrial cell death
pathways. Activation of the cell surface death receptor Fas
leads to the activation of caspase-8, which cleaves Bid [58].
Truncated Bid (tBid) is able to translocate to the mitochon-
dria and can induce mitochondrial cytochrome c release
[58]. This release may result from oligomerization or
conformational changes in Bak or Bax, events promoted
by tBid [61–63]. Bcl-XL and Bcl-2 are able to inhibit Bid-
dependent cytochrome c release from isolated mitochondria
[58,59,64]. Bid is expressed in neurons in both the embry-
onic and adult nervous systems [57,65], and tBid has been
shown to interact with Bak in brain mitochondria and induce
cytochrome c release [66]. However, Bid does not appear to
play a major role in regulating neuronal programmed cell
death during development. Bid-deficient mice exhibit no
gross or microscopic neuropathology and there is no effect
of Bid deficiency on naturally occurring neuronal cell death
[65,67]. Bid deficiency also has no effect on neural precur-
sor cell death either in vivo or in vitro [65]. Since the BH3-
only subfamily is large, it remains possible that other BH3-
only molecules subserve Bid function in Bid-deficient cells.
2.6. Bim
Bim was originally isolated as a pro-apoptotic, Bcl-2
interacting protein. Bim is a BH3-only subfamily member
and can interact with Bcl-2, Bcl-XL and Bcl-w. Bim has three
major splice variants, BimEL, BimL, and BimS, some of
which can bind Bax directly [68,69]. Bim is primarily
ysica Acta 1644 (2004) 189–203ematoxylin and eosin stained sections of the 4-week-old mouse brain show
panel: examples indicated by arrows) and a marked expansion of this cell
cale bars equal 200 Am.
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BimEL expression is induced after apoptotic stimuli in
several neuronal populations. In sympathetic neurons fol-
lowing NGF withdrawal, increased Bim expression is de-
pendent on JNK signaling and occurs upstream of Bax-
dependent caspase activation [71–73]. Similarly, cerebellar
granule neurons exposed to non-depolarizing, serum-free
conditions undergo Bax-dependent apoptosis that is accom-
panied by increased Bim expression [41,64,73]. The addition
of insulin-like growth factor 1 (IGF-1) in these conditions
can block Bim induction and death [74]. Although the
precise mechanisms that regulate Bim function in neuronal
cells are unclear, recently NGF has been shown to promote
the phosphorylation of Bim and thereby suppress its pro-
apoptotic activity [75].
Bim-deficient mice have been generated and show in-
completely penetrant, strain-dependent embryonic lethality
around E9.5 [76]. Programmed cell death of dorsal root
ganglion neurons at E14.5 may be mildly reduced in Bim-
deficient embryos but this effect appears transitory [72].
There are no obvious neuropathological abnormalities in
bim /  mice that survive to birth [76]. In vitro, Bim
deficiency may delay, but does not prevent, both trophic
factor withdrawal-induced sympathetic neuron death and
activity-dependent cerebellar granule neuron death [72].
Another study of postnatal dorsal root ganglion sensory
neurons has demonstrated that Bim deficiency provides
partial protection from trophic factor withdrawal-induced
death [71]. In total, these results suggest that Bim plays an
important, but not essential, role in regulating neuronal
programmed cell death.
2.7. DP5/Hrk
Death protein 5 (DP5) was identified through a total
mRNA differential display analysis of NGF-deprived sym-
pathetic neurons [77]. DP5 is highly homologous to the
human gene harakiri (Hrk), cloned by a two-hybrid screen
with Bcl-2 and Bcl-XL [78]. DP5 mRNA and protein are
expressed in several tissues and are developmentally regu-
lated in the nervous system [77,79]. Several in vitro systems
have demonstrated a role for DP5/Hrk in regulation of
neuronal cell death. Sympathetic neurons deprived of
NGF induce DP5 mRNA [77]. DP5 is up-regulated in
cerebellar granule neurons incubated in non-depolarizing,
serum-free media [73]. This up-regulation is independent of
Bax and incompletely blocked by inhibitors of JNK signal-
ing [73]. Finally, DP5 mRNA is induced in primary rat
cortical neurons exposed to toxic concentrations of amyloid-
h protein [80], and this induction is attenuated by inhibition
of JNK signaling [81]. These results suggest that several
cellular pathways control DP5 expression. Overexpression
of DP5 induces apoptosis in sympathetic neurons, and this
effect can be attenuated by co-expression of Bcl-2 [77]. Hrk
mRNA expression is relatively high in lymphoid tissues,
bone marrow, and spleen but is low in brain. Overexpressionof Hrk induces a dramatic loss in cell viability that is
prevented by co-expression of Bcl-2 or Bcl-XL. The inter-
action between Hrk and Bcl-2 or Bcl-XL is dependent on
Hrk’s BH3 domain [78]. It is unclear whether DP5/Hrk acts
by sequestering pro-survival Bcl-2 family members or by
direct interaction with pro-apoptotic molecules.
2.8. Bad
Bad, Bcl-2-associated death protein, is a BH3-only
subfamily member that was isolated as a binding partner
for both Bcl-XL and Bcl-2 [82]. Bad is widely expressed in
murine tissues, including the brain [83]. Bad is readily
detected in the embryonic nervous system and is down-
regulated postnatally [84]. The regulation of Bad function
by posttranslational modification has been extensively in-
vestigated and Bad phosphorylation may critically regulate
apoptosis in some cell types. At baseline, growth factor
signaling activates kinases that phosphorylate Bad, which
resides in an inactive state complexed with the molecular
chaperone protein 14-3-3 [85]. Following an apoptotic
stimulus, dephosphorylation of Bad may disrupt its com-
plex with 14-3-3, permitting its interaction with Bcl-XL and
producing downstream Bax-dependent cytochrome c re-
lease and caspase activation [85,86]. This mechanism has
been described in several in vitro neuronal systems. In
cultured rat hippocampal neurons, addition of transforming
growth factor-h1 increases Bad phosphorylation and
decreases the elevation of Bad protein following exposure
to apoptotic stimuli [87]. Overexpression of Bad in cere-
bellar granule neurons causes death that is very similar to
that seen following trophic factor withdrawal. Furthermore,
Akt, a mediator of growth factor-induced survival in many
cell types, can phosphorylate Bad, and expression of active
Akt can prevent Bad-induced cell death in this system [88].
Similarly, overexpression of Bad in mature sympathetic
neurons induces death [89]. Clearly, phosphorylation of
Bad is an important regulatory mechanism in neuronal cell
populations. It is important to note that Bad can be
phosphorylated on several sites, and not all phosphorylation
events prevent Bad’s pro-apoptotic function. For example,
both growth factor signaling and stimulation of JNK sig-
naling induce Bad phosphorylation in cerebellar granule
neurons. JNK-induced phosphorylation of Bad may make it
less susceptible to phosphorylation by growth factor sig-
naling and may thereby promote Bad-mediated apoptosis
[90].
Bad-deficient mice have been generated but show no
gross developmental abnormalities, neurodevelopmental ab-
normalities, or alteration in neuronal programmed cell death
[23,83]. Bad has been implicated in several neuronal cell
death models both in vivo and in vitro but the lack of an
effect on neuronal programmed cell death in vivo suggests
that Bad does not critically regulate naturally occurring
neuronal cell death. Transgenic knock-in mice have been
generated that express non-phosphorylatable mutant Bad.
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ing in lymphocytes but no gross abnormalities in neural
tissues [91]. As mentioned, in non-depolarizing, serum-free
conditions, cerebellar granule neurons undergo apoptosis
that is blocked by the addition of IGF-1 [40,74]. This effect
of IGF-1 is absent in mice expressing non-phosphorylatable
Bad, suggesting that pro-survival growth factor signaling in
neuronal cells is directly linked to Bad phosphorylation
[91].
2.9. Noxa
Noxa, a BH3-only member of the Bcl-2 family, was
identified by mRNA differential display as a being expressed
in X-ray-irradiated mouse embryonic fibroblasts (MEFs)
[92]. Noxa is unique in that it harbors two BH3 domains.
Noxa is expressed in several adult mouse tissues, including
brain, and localizes to the mitochondria [92,93]. Noxa is
inducible by p53, a tumor-suppressor protein that is critical
for preventing the growth of abnormal or damaged cells. p53
inhibits growth by inducing both cell cycle arrest and cell
death, although it is not entirely clear how p53-mediated
signals are transmitted to the cell death machinery. The fact
that Noxa is both a transcriptional target of p53 and a pro-
apoptotic member of the Bcl-2 family strongly suggests that
it may have a role in mediating p53-dependent signals that
control entry into intrinsic cell death pathways. Although
detailed investigations of Noxa function in neuronal cell
death are currently lacking, the role of Noxa in non-neuronal
systems has been studied. In MEFs, Noxa expression is p53-
dependent and can be induced by concomitant p53 over-
expression [94]. Furthermore, Noxa knockdown using inter-
fering RNA oligonucleotides protects MEFs from a variety
of apoptosis-inducing agents [94]. Overexpression of Noxa
in several human cancer cell lines induces cytochrome c
release, caspase-9 activation, and apoptosis [92,93]. These
studies provide the groundwork for further investigations of
Noxa function in neuronal cell types to determine this
molecule’s contribution to neuronal apoptosis.
Noxa deficient mice have recently been generated, and
display no obvious developmental abnormalities [95,96].
Embryonic fibroblasts isolated from Noxa-deficient mice
show resistance to several apoptotic stimuli [95]. Further-
more, membrane insertion of Bax and Bax oligomerization
is decreased in Noxa-deficient MEFs as compared to wild-
type MEFs, suggesting that Noxa may promote the actions
of Bax [95]. Recombinant Noxa can induce cytochrome c
release without Bak-oligomerization, suggesting that Noxa
and Bax may act synergistically [93].
2.10. Puma
Puma, a BH3-only member of the Bcl-2 family, was
simultaneously identified by a microarray screen and a serial
analysis of gene expression method [97,98]. Puma, like
Noxa, is induced by p53 and may play a role in couplingdeath stimuli to effectors of apoptosis. Puma binds Bcl-2
and localizes to the mitochondria, where it induces cyto-
chrome c release [97,98]. In addition, Puma has been shown
to interact with Bcl-XL [98]. Puma also activates caspase-9
and caspase-3 in a number of cell lines in a BH3-domain-
dependent manner, followed by rapid onset of morpholog-
ical apoptotic features [97,98].
Currently, Puma’s role in regulating neuronal cell death
is unclear. Puma mRNA and protein expression are in-
creased in SH-SY5Y human neuroblastoma cells exposed
to endoplasmic reticulum (ER) stress. This expression is
followed by increased caspase-3 like protease activity and
apoptotic nuclear features [99]. Interestingly, this study did
not find an increase in mRNA levels of Bim, Bad, Noxa,
Bax, Bak, Bcl-2 or Bcl-x in this model. ER stress in SH-
SY5Y cells causes mitochondrial localization of Bax as well
as release of cytochrome c [99]. Puma-deficient mice have
recently been generated, and show no abnormalities in
organogenesis or neurodevelopment. Puma deficiency pro-
vides marked resistance to several apoptosis-inducing
agents in non-neuronal cell types [96]. Further experimen-
tation is required to determine the role Puma deficiency may
play in regulating neuronal cell death. Such studies are
warranted considering that gene targeting of Puma in a
colorectal cancer cell line has demonstrated a critical role for
the molecule in p53-dependent cell death induced by DNA
damage, hypoxia, or ER stress [99,100].
In total, studies of genetically-modified mice have
revealed a significant role for the Bcl-2 family in regulating
neuronal programmed cell death. Particularly significant
roles for Bcl-XL and Bax are apparent and their action is
complemented by Bcl-2 and Bak, respectively. Although
disruption of individual BH3-only genes has not resulted in
obvious changes in neuronal programmed cell death, it
remains likely that this Bcl-2 subfamily acts in concert to
regulate neuronal cell death.3. Bcl-2 family regulation of neurodegeneration
Given the clear role for Bcl-2 family members in
regulating cell death during nervous system development,
much interest has been given to Bcl-2 family involvement in
neuropathological conditions. The mammalian nervous sys-
tem has several unique features that make it susceptible to
injury and thus, regulation of neuronal cell death is of
paramount significance. First, neural tissue is exquisitely
sensitive to hypoxia and ischemia. Second, neurons are
excitable and neural activity is imperative for neuron
survival and function. Third, dead neurons, with rare ex-
ception, are not replaced in the mature nervous system, and
the activation of a ‘‘cell suicide’’ death program may have
significant and permanent impact on nervous system func-
tion. Fourth, since neurons are long-lived, sublethal injuri-
ous stimuli may produce changes in cell death-associated
molecules that may attenuate or exacerbate the effects of
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that interfere with synaptic transmission may render a
neuron dysfunctional even in the absence of neuron death.
Apoptosis-associated molecules may therefore be involved
in neurodegenerative processes prior to, or in the absence of,
neuron death.
3.1. Hypoxic-ischemic injury
Cerebrovascular disease is one of the leading causes of
human morbidity and mortality worldwide. The brain is
particularly vulnerable to hypoxic-ischemic injury that may
occur focally or globally, as seen in stroke or asphyxiation,
respectively. The role of Bcl-2 family members in regulating
neuron death has been extensively investigated in animal
models of hypoxic-ischemic neuronal injury. Neuronal
expression of Bcl-2 family members appears to be altered
by hypoxic-ischemic injury both in vivo and in vitro
[27,101,102]. Exposure to hypoxia alone can increase Bcl-
2 immunoreactivity in cultured neocortical cells, and several
in vivo rodent models of hypoxic-ischemic injury have
demonstrated increased Bcl-2 immunoreactivity [101–
103]. However, elevated Bcl-2 expression has not been
observed in all animal models of hypoxic-ischemic brain
injury and it appears that Bcl-2 expression may be influ-
enced by the degree of insult, species-specific factors, and
gender-specific factors [101,104–106].
Further evidence for the potential importance of anti-
apoptotic Bcl-2 family members has been demonstrated in
experiments that manipulate protein expression of Bcl-2,
Bcl-XL or Bcl-w. Overexpression of Bcl-2 in mice partially
protects against stroke-induced injury [14]. Furthermore,
intraventricular infusion of Bcl-2 antisense oligonucleotides
accentuated stroke size following middle cerebral artery
occlusion in rat [107] and prevented tolerance to subsequent
ischemia [108].
In many, but not all, hypoxic-ischemic models, direct
CNS injection of viral vectors to drive overexpression of
anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-XL,
and Bcl-w has resulted in significant diminution in neuronal
cell death and infarct size [109–118]. A novel alternative
approach has fused Bcl-XL [117] or phosphorylation-resis-
tant Bcl-XL [119] to the protein transduction domain (PTD)
of the human immunodeficiency virus (HIV) TAT protein.
These fusion proteins penetrate the blood–brain barrier
following intraperitoneal injection, and significantly in-
crease the efficacy of the anti-apoptotic vectors.
The analysis of mice with targeted gene disruptions has
confirmed the significance of specific Bcl-2 family members
in the regulation of neuronal responsiveness to hypoxic-
ischemic injury. Bcl-2-deficient mice show increased infarct
size and more severe neurological deficits following tran-
sient middle cerebral artery occlusion as compared to
heterozygous and wild-type littermates [120]. In contrast,
Bax-deficient mice exhibit significantly decreased caspase-3
activation and infarct volume as compared to wild types in aneonatal hypoxic-ischemic injury model [121]. Similarly,
Bid-deficient mice subjected to transient middle cerebral
artery occlusion had decreased cytochrome c release, cas-
pase-3 activation, and infarct size compared to wild-type
animals [122,123]. In total, these studies suggest that the
expression of pro- and anti-apoptotic Bcl-2 family members
critically regulates responsiveness to hypoxic-ischemic in-
jury and that inhibition of Bcl-2 family-dependent death
pathways could offer significant protection from cerebro-
vascular insults.
3.2. Seizure-induced neurodegeneration
Abundant evidence exists for neuronal cell death follow-
ing significantly intense seizure activity [124,125]. A com-
plex pattern of apoptotic, excitotoxic, and necrotic death
pathways may be activated following seizure activity [124,
126–128]. Changes in Bcl-2 family member expression have
been observed in several experimental models of seizures
induced by kainic acid, domoic acid, or electrical stimulation.
Most often reported has been increased neuronal expression
of Bax mRNA and protein [129–132]. Changes in Bcl-2
expression have not been consistently observed and various
seizure models have produced increased, decreased, or unal-
tered Bcl-2 expression [129,130,132]. Bid, Bad, caspase-8,
caspase-9, and caspase-3 have all been reported to be acti-
vated in seizure-induced neuronal death [133–135]. Unfor-
tunately, overexpression of Bcl-2 has not consistently led to
neuroprotection in animal models of seizure-induced neuro-
toxicity [136,137]. Studies of mice with targeted gene dis-
ruptions in Bcl-2 family members have been sparse. One
study of Bak-deficient mice treated with kainic acid demon-
strated increased seizure activity and greater hippocampal
cell loss in bak  / compared to bak+/ animals, suggesting
that Bak may modulate both neuronal excitability and cell
death pathways [138]. Additional studies are required before
any conclusions about the significance of Bcl-2 family
involvement in seizure-induced neuron death can be drawn.
3.3. Motor neuron disease
Amyotrophic lateral sclerosis (ALS) is a neurodegener-
ative disease affecting upper motor neurons in the cerebral
cortex and lower motor neurons in the spinal cord. In ALS,
death of motor neurons leads to a progressive loss of
voluntary muscle function and ultimately respiratory failure
and death over a typical course of several years. Most cases
of ALS are sporadic but approximately 10% of cases are
familial. In familial ALS, the onset of disease typically
occurs at a younger age and proceeds more rapidly than in
sporadic ALS. One familial ALS subtype has been linked to
mutations in the gene for copper/zinc superoxide dismutase-
1 (SOD1), a free radical-scavenging enzyme [139,140].
Overexpression of mutated SOD1 in transgenic mouse and
rat models leads to motor neuron loss through a proposed
toxic gain-of-function effect [141–144].
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the regulation of motor neuron death in this disease.
Decreased expression of Bcl-2 mRNA [145] and increased
expression of harakiri mRNA [146] and Bax mRNA and
protein [145,147] have been reported in ALS. This change
in the balance of pro- and anti-apoptotic Bcl-2 family
molecules, coupled with a reported increase in Bax and
Bak mitochondrial localization and increased Bcl-2 cytosol-
ic distribution, may contribute to neuron death in ALS
[145,147–149].
Studies of mutant SOD1-overexpressing transgenic ani-
mals also support a role for the Bcl-2 family in motor
neuron disease. As the disease progresses, mRNA and
protein levels of Bcl-2 and Bcl-XL decrease, while Bax
and Bad levels increase in motor neurons of mutant SOD1
transgenic mice [150–152]. Translocation of Bax and Bak
from the cytosol to the mitochondria has also been shown to
correlate with disease progression in SOD1-overexpressing
mice [148,149]. In addition, increased Bid cleavage is
detected in SOD1 mutant mice as compared to wild-type
controls [153]. Studies of Bcl-2 transgenic and knock-out
mice also implicate the Bcl-2 family in motor neuron
disease pathogenesis. Overexpression of Bcl-2 in SOD1
transgenic mice results in delayed onset of symptoms and
increased survival [154,155]. This neuron survival-promot-
ing effect appears to result from a neutralization of Bax’s
pro-apoptotic function and inhibition of caspase-1, -9, and -
3 activity [150,156]. However, Bcl-2 overexpression fails to
protect motoneurons from death in a second transgenic
model of ALS [157], and morphologic studies of transgenic
animal models and human ALS brain and spinal cord have
provided limited evidence that neuron loss in ALS occurs
via apoptotic death pathways [147,158]. Additional studies
are required to determine the significance of the Bcl-2
family in the pathogenesis of motor neuron disease.
3.4. Nerve injury
Peripheral nerve injury may often lead to neuronal cell
death. In early postnatal rodents, lesions of the facial or
sciatic nerve cause rapid motoneuron degeneration in their
respective nuclei [159–161], and transection of the optic
nerve causes degeneration in retinal ganglion cells (RGCs)
in both neonatal and adult mice [162,163]. Changes in
neuronal expression of Bcl-2 family members following
axotomy suggest a role for these proteins in regulating
axotomy-induced neuron death. Bcl-2 mRNA and protein
may either decrease or increase depending on the site of
axotomy and type of injury [164–169]. Bax mRNA and
protein have consistently been reported to be increased in
neurons post-axotomy, and, combined with altered Bcl-XL
and BimEL expression, may favor neuronal degeneration
[72,164–167]. Overexpression of Bcl-2 or Bcl-XL in axo-
tomized neurons is neuroprotective in many experimental
models [11,114,162,163,170–173]. For example, Bcl-2-
overexpressing transgenic mice have decreased RGC deathfollowing optic nerve transection. This effect is seen in both
neonates and adults [163,165]. Based on electroretinogra-
phy, RGC function in these animals is preserved [174,175].
Similarly, Bax-deficient mice show significant protection
from facial nerve axotomy-induced neuron loss [35]. These
studies indicate that Bcl-2 family members play an impor-
tant role in regulating neuron loss following axonal injury.
3.5. Ethanol-induced neonatal brain injury
The neonatal rodent brain, which is roughly develop-
mentally equivalent to the perinatal human brain, shows a
marked sensitivity to a variety of insults. Olney and col-
leagues have reported extensive caspase-3 activation and
apoptotic neuronal degeneration throughout the central
nervous system of neonatal rats and/or mice exposed to
antiepileptic drugs, anesthetic agents, or ethanol [176–179].
Prenatal or early postnatal ethanol exposure results in
relative increases of Bax and Bcl-XS mRNA and protein
levels as compared to Bcl-2 in the cerebellum and cortex
[180–182]. Additionally, transgenic neonatal mice over-
expressing Bcl-2 are protected against ethanol-induced
neuronal cell death [180]. The role of pro-apoptotic Bcl-2
family members in ethanol-induced neuronal apoptosis has
been examined in Bax-deficient neonatal mice [183]. Unlike
wild-type mice, ethanol-exposed Bax-deficient animals
show no increase in caspase-3 activity, TUNEL staining,
or apoptotic neurons (Fig. 3). Quantitative determination of
neuron density in ethanol-exposed wild-type and Bax-defi-
cient neonatal mice showed a marked loss of neurons in
wild-type mice, but no loss of neurons either 24 or 72 h after
ethanol exposure in Bax-deficient mice, indicating that Bax
deficiency provides prolonged protection from ethanol-in-
duced neuronal degeneration. These studies suggest that
Bax, and likely other Bcl-2 family members, play an
important function during the perinatal period of human
nervous system development.
3.6. Non-apoptotic neurodegeneration
Although some authors have suggested that caspase-
dependent apoptosis underlies the pathogenesis of human
neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, and Huntington’s disease, this view
has recently been questioned [2,184,185]. Specifically, there
is relatively little morphological evidence for apoptosis in
human neurodegenerative diseases and several alternative
forms of cell death have been described. Increasing attention
has focused on caspase-independent death pathways and,
particularly, the occurrence and regulation of autophagic
neuronal degeneration [186,187]. Evidence for Bcl-2 family
involvement in autophagic cell death has been provided in
several studies. Bid cleavage has been demonstrated fol-
lowing lysosomal damage [188,189]. Furthermore, an in
vitro model of autophagic cell death revealed increased
susceptibility of Bcl-XL-deficient neurons and decreased
Fig. 3. Bax deficiency protects neonatal neurons from ethanol-induced neurodegeneration. In wild-type neonatal mice (left panel), acute ethanol intoxication
produces widespread caspase-3 activation (detected with antibodies specific for cleaved, ‘‘activated,’’ caspase-3; red, examples indicated by arrows) and
neuronal apoptosis (apoptotic nuclear features are identified by Hoechst 33,258 staining; blue) in the brain. In contrast, ethanol-exposed Bax-deficient neonatal
mice show no increase in activated caspase-3 immunostaining or apoptotic neurons (right panel). Scale bars equal 50 Am.
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agents [22]. This degenerative process may involve Bcl-2
family-dependent mitochondrial injury and degradation
[190]. Interestingly, autophagy has been reported in meth-
amphetamine-induced dopaminergic neuritic degeneration,
and steroid-induced neuronal cell death may also involve
mitochondrial injury and autophagic pathways [191–193].
Regardless of the type of neuronal death induced, over-
expression of anti-apoptotic Bcl-2 family members or bax
gene disruption provides significant neuroprotection in
several in vivo and in vitro disease degenerative models
[194–196]. The protective effects of Bcl-2 overexpression
or bax gene disruption can be cell-specific. Lurcher mice
express a mutant, constitutively active glutamate receptor in
cerebellar Purkinje cells [197]. The resultant increase in
inward depolarizing current leads to the loss of Purkinje
cells, followed by a secondary loss of cerebellar granule
neurons. In Lurcher animals, apoptotic Purkinje cells ex-
press increased levels of Bax [198]. Recently, Bax-deficient,
Lurcher double mutants were generated. In Bax-deficient/
Lurcher animals, the secondary loss of cerebellar granule
cell neurons is blocked; however, Purkinje cell death is
delayed but not prevented, suggesting the involvement of
Bax-independent cell death pathways in this cell population
[195,199].
In summary, both pro-survival and pro-death members of
the Bcl-2 family play an essential role in normal nervous
system development and are likely critical factors in certain
neurological disease processes. In the nervous system, the
expression of individual Bcl-2 family members and their
contribution to survival or death are developmentally regu-
lated. Both pro-survival and pro-death Bcl-2 family mem-
bers play an essential role in normal nervous system
development as illustrated by transgenic mouse strains with
single or double gene disruptions of Bcl-2 family molecules.
The very importance of this family is underscored by the
functional redundancy of many of its members. Further-
more, the regulation of these molecules is complex, and may
include mechanisms of transcriptional, translational, andposttranslational control. In many neurological disease
models, altered Bcl-2 family member mRNA and protein
expression has been observed. These findings provide hope
that development of targeted pharmacological agents that
enhance anti-apoptotic Bcl-2 family function or inhibit pro-
apoptotic Bcl-2 family function will prove useful in the
treatment of human neuropathological conditions. These
interventions may block both apoptotic and non-apoptotic
forms of neurodegeneration. In conclusion, the continued
investigation of the basic biology of Bcl-2 family members
in neuron populations will certainly make an impact on
understanding neurodevelopment and neurodegeneration.Acknowledgements
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